Results from the CREDENCE and CARMELINA clinical trials, both of which targeted patients with type 2 diabetes and chronic kidney disease, will be presented at 7:30 a.m. in N-Hall E (North, Exhibition Level). CARMELINA study co-chair Darren K. McGuire, MD, MHSc, discussed the background, objective, and significance of the trial with ADAMeetingNews.org.
Beginning soon: CREDENCE and CARMELINA—Results from Two Major Clinical Trials in Kidney and Cardiovascular Disease in Diabetes
Darren K. McGuire, MD, MHSc
